Arrowhead Pharmaceuticals, Inc. (ARWR) FinancialsARWRArrowhead Pharmaceuticals, Inc.

Evaluating the bottom line, Arrowhead Pharmaceuticals, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -226.03%, while the net margin is -237.75%. These profitability ratios, combined with a Return on Equity (ROE) of -64.78%, provide a clear picture of how effectively ARWR converts its operational activities into shareholder value.

In the context of the broader market, ARWR competes directly with industry leaders such as HALO and ELAN. With a market capitalization of $12.51B, it holds a leading position in the sector. When comparing efficiency, ARWR's gross margin of 100.00% stands against HALO's 77.40% and ELAN's 48.17%. Such benchmarking helps identify whether Arrowhead Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Arrowhead reported approximately $75 million in revenue for Q3 2026, with a net loss of $194.3 million, but maintains a strong cash position of $1.6 billion, indicating resilience.